COVID-19 Monoclonal Antibodies: FDA Authorizes Bebtelovimab

On February 11, the Food and Drug Administration (FDA) authorized the emergency use of the monoclonal antibody bebtelovimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients when all of these apply:

• They have a positive COVID-19 test result
• They’re at high risk for progression to severe COVID-19
• Alternative COVID-19 treatment options approved or authorized by the FDA aren’t accessible or clinically appropriate for them

CMS created new codes, effective February 11:

Q0222:

• Long descriptor: Injection, bebtelovimab, 175 mg
• Short descriptor: Bebtelovimab 175

M0222:

• Long descriptor: Intravenous injection, bebtelovimab, includes injection and post-administration monitoring
• Short descriptor: Bebtelovimab injection

M0223:

• Long descriptor: Intravenous injection, bebtelovimab, includes injection and post-administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the COVID-19 public health emergency
• Short descriptor: Bebtelovimab injection home

Visit the COVID-19 Monoclonal Antibodies webpage for more information.